Global siRNA Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global siRNA Drugs market size was valued at US$ 3642 million in 2025 and is forecast to a readjusted size of US$ 20400 million by 2032 with a CAGR of 28.2% during review period.
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20?24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
'The 14th Five-Year Plan for the Development of the Pharmaceutical Industry': Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide 'one-stop' services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the 'patent pool' model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
The siRNA Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
siRNA Drugs market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type,
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20?24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
'The 14th Five-Year Plan for the Development of the Pharmaceutical Industry': Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide 'one-stop' services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the 'patent pool' model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
The siRNA Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
siRNA Drugs market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type,
- Intravenous Injection
- Subcutaneous Injection
- Nervous System Therapy
- Endocrine and Metabolic Therapy
- Others
- Alnylam
- Novartis
- Novo Nordisk
- Genzyme
- Arrowhead
- Silence
- Sylentis
- Avidity Biosciences
- Sirnaomics
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa
1 MARKET OVERVIEW
1.1 Product Overview and Scope of siRNA Drugs
1.2 Classification of siRNA Drugs by Type
1.2.1 Overview: Global siRNA Drugs Market Size by Type: 2026 Versus 2032
1.2.2 Global siRNA Drugs Revenue Market Share by Type in 2032
1.2.3 Intravenous Injection
1.2.4 Subcutaneous Injection
1.3 Global siRNA Drugs Market by Application
1.3.1 Overview: Global siRNA Drugs Market Size by Application: 2026 Versus 2032
1.3.2 Nervous System Therapy
1.3.3 Endocrine and Metabolic Therapy
1.3.4 Others
1.4 Global siRNA Drugs Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
1.5.1 siRNA Drugs Market Drivers
1.5.2 siRNA Drugs Market Restraints
1.5.3 siRNA Drugs Trends Analysis
2 COMPANY PROFILES
2.1 Alnylam
2.1.1 Alnylam Details
2.1.2 Alnylam Major Business
2.1.3 Alnylam siRNA Drugs Product and Solutions
2.1.4 Alnylam Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis siRNA Drugs Product and Solutions
2.2.4 Novartis Recent Developments and Future Plans
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business
2.3.3 Novo Nordisk siRNA Drugs Product and Solutions
2.3.4 Novo Nordisk Recent Developments and Future Plans
2.4 Genzyme
2.4.1 Genzyme Details
2.4.2 Genzyme Major Business
2.4.3 Genzyme siRNA Drugs Product and Solutions
2.4.4 Genzyme Recent Developments and Future Plans
2.5 Arrowhead
2.5.1 Arrowhead Details
2.5.2 Arrowhead Major Business
2.5.3 Arrowhead siRNA Drugs Product and Solutions
2.5.4 Arrowhead Recent Developments and Future Plans
2.6 Silence
2.6.1 Silence Details
2.6.2 Silence Major Business
2.6.3 Silence siRNA Drugs Product and Solutions
2.6.4 Silence Recent Developments and Future Plans
2.7 Sylentis
2.7.1 Sylentis Details
2.7.2 Sylentis Major Business
2.7.3 Sylentis siRNA Drugs Product and Solutions
2.7.4 Sylentis Recent Developments and Future Plans
2.8 Avidity Biosciences
2.8.1 Avidity Biosciences Details
2.8.2 Avidity Biosciences Major Business
2.8.3 Avidity Biosciences siRNA Drugs Product and Solutions
2.8.4 Avidity Biosciences Recent Developments and Future Plans
2.9 Sirnaomics
2.9.1 Sirnaomics Details
2.9.2 Sirnaomics Major Business
2.9.3 Sirnaomics siRNA Drugs Product and Solutions
2.9.4 Sirnaomics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global siRNA Drugs Revenue and Share by Players (2026 & 2032)
3.2 siRNA Drugs Players Head Office, Products and Services Provided
3.3 siRNA Drugs Mergers & Acquisitions
3.4 siRNA Drugs New Entrants and Expansion Plans
4 GLOBAL SIRNA DRUGS FORECAST BY REGION
4.1 Global siRNA Drugs Market Size by Region: 2026 VS 2032
4.2 Global siRNA Drugs Market Size by Region, (2026-2032)
4.3 North America
4.3.1 Key Companies of siRNA Drugs in North America
4.3.2 Current Situation and Forecast of siRNA Drugs in North America
4.3.3 North America siRNA Drugs Market Size and Prospect (2026-2032)
4.4 Europe
4.4.1 Key Companies of siRNA Drugs in Europe
4.4.2 Current Situation and Forecast of siRNA Drugs in Europe
4.4.3 Europe siRNA Drugs Market Size and Prospect (2026-2032)
4.5 Asia-Pacific
4.5.1 Key Companies of siRNA Drugs in Asia-Pacific
4.5.2 Current Situation and Forecast of siRNA Drugs in Asia-Pacific
4.5.3 Asia-Pacific siRNA Drugs Market Size and Prospect (2026-2032)
4.5.4 China
4.5.5 Japan
4.5.6 South Korea
4.6 South America
4.6.1 Key Companies of siRNA Drugs in South America
4.6.2 Current Situation and Forecast of siRNA Drugs in South America
4.6.3 South America siRNA Drugs Market Size and Prospect (2026-2032)
4.7 Middle East & Africa
4.7.1 Key Companies of siRNA Drugs in Middle East & Africa
4.7.2 Current Situation and Forecast of siRNA Drugs in Middle East & Africa
4.7.3 Middle East & Africa siRNA Drugs Market Size and Prospect (2026-2032)
5 MARKET SIZE SEGMENT BY TYPE
5.1 Global siRNA Drugs Market Forecast by Type (2026-2032)
5.2 Global siRNA Drugs Market Share Forecast by Type (2026-2032)
6 MARKET SIZE SEGMENT BY APPLICATION
6.1 Global siRNA Drugs Market Forecast by Application (2026-2032)
6.2 Global siRNA Drugs Market Share Forecast by Application (2026-2032)
7 RESEARCH FINDINGS AND CONCLUSION
8 APPENDIX
8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer
1.1 Product Overview and Scope of siRNA Drugs
1.2 Classification of siRNA Drugs by Type
1.2.1 Overview: Global siRNA Drugs Market Size by Type: 2026 Versus 2032
1.2.2 Global siRNA Drugs Revenue Market Share by Type in 2032
1.2.3 Intravenous Injection
1.2.4 Subcutaneous Injection
1.3 Global siRNA Drugs Market by Application
1.3.1 Overview: Global siRNA Drugs Market Size by Application: 2026 Versus 2032
1.3.2 Nervous System Therapy
1.3.3 Endocrine and Metabolic Therapy
1.3.4 Others
1.4 Global siRNA Drugs Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
1.5.1 siRNA Drugs Market Drivers
1.5.2 siRNA Drugs Market Restraints
1.5.3 siRNA Drugs Trends Analysis
2 COMPANY PROFILES
2.1 Alnylam
2.1.1 Alnylam Details
2.1.2 Alnylam Major Business
2.1.3 Alnylam siRNA Drugs Product and Solutions
2.1.4 Alnylam Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis siRNA Drugs Product and Solutions
2.2.4 Novartis Recent Developments and Future Plans
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business
2.3.3 Novo Nordisk siRNA Drugs Product and Solutions
2.3.4 Novo Nordisk Recent Developments and Future Plans
2.4 Genzyme
2.4.1 Genzyme Details
2.4.2 Genzyme Major Business
2.4.3 Genzyme siRNA Drugs Product and Solutions
2.4.4 Genzyme Recent Developments and Future Plans
2.5 Arrowhead
2.5.1 Arrowhead Details
2.5.2 Arrowhead Major Business
2.5.3 Arrowhead siRNA Drugs Product and Solutions
2.5.4 Arrowhead Recent Developments and Future Plans
2.6 Silence
2.6.1 Silence Details
2.6.2 Silence Major Business
2.6.3 Silence siRNA Drugs Product and Solutions
2.6.4 Silence Recent Developments and Future Plans
2.7 Sylentis
2.7.1 Sylentis Details
2.7.2 Sylentis Major Business
2.7.3 Sylentis siRNA Drugs Product and Solutions
2.7.4 Sylentis Recent Developments and Future Plans
2.8 Avidity Biosciences
2.8.1 Avidity Biosciences Details
2.8.2 Avidity Biosciences Major Business
2.8.3 Avidity Biosciences siRNA Drugs Product and Solutions
2.8.4 Avidity Biosciences Recent Developments and Future Plans
2.9 Sirnaomics
2.9.1 Sirnaomics Details
2.9.2 Sirnaomics Major Business
2.9.3 Sirnaomics siRNA Drugs Product and Solutions
2.9.4 Sirnaomics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global siRNA Drugs Revenue and Share by Players (2026 & 2032)
3.2 siRNA Drugs Players Head Office, Products and Services Provided
3.3 siRNA Drugs Mergers & Acquisitions
3.4 siRNA Drugs New Entrants and Expansion Plans
4 GLOBAL SIRNA DRUGS FORECAST BY REGION
4.1 Global siRNA Drugs Market Size by Region: 2026 VS 2032
4.2 Global siRNA Drugs Market Size by Region, (2026-2032)
4.3 North America
4.3.1 Key Companies of siRNA Drugs in North America
4.3.2 Current Situation and Forecast of siRNA Drugs in North America
4.3.3 North America siRNA Drugs Market Size and Prospect (2026-2032)
4.4 Europe
4.4.1 Key Companies of siRNA Drugs in Europe
4.4.2 Current Situation and Forecast of siRNA Drugs in Europe
4.4.3 Europe siRNA Drugs Market Size and Prospect (2026-2032)
4.5 Asia-Pacific
4.5.1 Key Companies of siRNA Drugs in Asia-Pacific
4.5.2 Current Situation and Forecast of siRNA Drugs in Asia-Pacific
4.5.3 Asia-Pacific siRNA Drugs Market Size and Prospect (2026-2032)
4.5.4 China
4.5.5 Japan
4.5.6 South Korea
4.6 South America
4.6.1 Key Companies of siRNA Drugs in South America
4.6.2 Current Situation and Forecast of siRNA Drugs in South America
4.6.3 South America siRNA Drugs Market Size and Prospect (2026-2032)
4.7 Middle East & Africa
4.7.1 Key Companies of siRNA Drugs in Middle East & Africa
4.7.2 Current Situation and Forecast of siRNA Drugs in Middle East & Africa
4.7.3 Middle East & Africa siRNA Drugs Market Size and Prospect (2026-2032)
5 MARKET SIZE SEGMENT BY TYPE
5.1 Global siRNA Drugs Market Forecast by Type (2026-2032)
5.2 Global siRNA Drugs Market Share Forecast by Type (2026-2032)
6 MARKET SIZE SEGMENT BY APPLICATION
6.1 Global siRNA Drugs Market Forecast by Application (2026-2032)
6.2 Global siRNA Drugs Market Share Forecast by Application (2026-2032)
7 RESEARCH FINDINGS AND CONCLUSION
8 APPENDIX
8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer
LIST OF FIGURES
Table 1. Global siRNA Drugs Revenue by Type, (USD Million) 2026 VS 2032
Table 2. Global siRNA Drugs Revenue by Application, (USD Million), 2026 VS 2032
Table 3. Alnylam Corporate Information, Head Office, and Major Competitors
Table 4. Alnylam Major Business
Table 5. Alnylam siRNA Drugs Product and Solutions
Table 6. Novartis Corporate Information, Head Office, and Major Competitors
Table 7. Novartis Major Business
Table 8. Novartis siRNA Drugs Product and Solutions
Table 9. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 10. Novo Nordisk Major Business
Table 11. Novo Nordisk siRNA Drugs Product and Solutions
Table 12. Genzyme Corporate Information, Head Office, and Major Competitors
Table 13. Genzyme Major Business
Table 14. Genzyme siRNA Drugs Product and Solutions
Table 15. Arrowhead Corporate Information, Head Office, and Major Competitors
Table 16. Arrowhead Major Business
Table 17. Arrowhead siRNA Drugs Product and Solutions
Table 18. Silence Corporate Information, Head Office, and Major Competitors
Table 19. Silence Major Business
Table 20. Silence siRNA Drugs Product and Solutions
Table 21. Sylentis Corporate Information, Head Office, and Major Competitors
Table 22. Sylentis Major Business
Table 23. Sylentis siRNA Drugs Product and Solutions
Table 24. Avidity Biosciences Corporate Information, Head Office, and Major Competitors
Table 25. Avidity Biosciences Major Business
Table 26. Avidity Biosciences siRNA Drugs Product and Solutions
Table 27. Sirnaomics Corporate Information, Head Office, and Major Competitors
Table 28. Sirnaomics Major Business
Table 29. Sirnaomics siRNA Drugs Product and Solutions
Table 30. Global siRNA Drugs Revenue (USD Million) by Players (2026 & 2032)
Table 31. Global siRNA Drugs Revenue Share by Players (2026 & 2032)
Table 32. siRNA Drugs Players Head Office, Products and Services Provided
Table 33. siRNA Drugs Mergers & Acquisitions in the Past Five Years
Table 34. siRNA Drugs New Entrants and Expansion Plans
Table 35. Global Market siRNA Drugs Revenue (USD Million) Comparison by Region (2026 VS 2032)
Table 36. Global siRNA Drugs Revenue Market Share by Region (2026-2032)
Table 37. Key Companies of siRNA Drugs in North America
Table 38. Current Situation and Forecast of siRNA Drugs in North America
Table 39. Key Companies of siRNA Drugs in Europe
Table 40. Current Situation and Forecast of siRNA Drugs in Europe
Table 41. Key Companies of siRNA Drugs in Asia-Pacific
Table 42. Current Situation and Forecast of siRNA Drugs in Asia-Pacific
Table 43. Key Companies of siRNA Drugs in China
Table 44. Key Companies of siRNA Drugs in Japan
Table 45. Key Companies of siRNA Drugs in South Korea
Table 46. Key Companies of siRNA Drugs in South America
Table 47. Current Situation and Forecast of siRNA Drugs in South America
Table 48. Key Companies of siRNA Drugs in Middle East & Africa
Table 49. Current Situation and Forecast of siRNA Drugs in Middle East & Africa
Table 50. Global siRNA Drugs Revenue Forecast by Type (2026-2032)
Table 51. Global siRNA Drugs Revenue Forecast by Application (2026-2032)
LIST OF FIGURES
Figure 1. siRNA Drugs Picture
Figure 2. Global siRNA Drugs Revenue Market Share by Type in 2032
Figure 3. Intravenous Injection
Figure 4. Subcutaneous Injection
Figure 5. siRNA Drugs Revenue Market Share by Application in 2032
Figure 6. Nervous System Therapy Picture
Figure 7. Endocrine and Metabolic Therapy Picture
Figure 8. Others Picture
Figure 9. Global siRNA Drugs Market Size, (USD Million): 2026 VS 2032
Figure 10. Global siRNA Drugs Revenue and Forecast (2026-2032) & (USD Million)
Figure 11. siRNA Drugs Market Drivers
Figure 12. siRNA Drugs Market Restraints
Figure 13. siRNA Drugs Market Trends
Figure 14. Alnylam Recent Developments and Future Plans
Figure 15. Novartis Recent Developments and Future Plans
Figure 16. Novo Nordisk Recent Developments and Future Plans
Figure 17. Genzyme Recent Developments and Future Plans
Figure 18. Arrowhead Recent Developments and Future Plans
Figure 19. Silence Recent Developments and Future Plans
Figure 20. Sylentis Recent Developments and Future Plans
Figure 21. Avidity Biosciences Recent Developments and Future Plans
Figure 22. Sirnaomics Recent Developments and Future Plans
Figure 23. Global siRNA Drugs Revenue Market Share by Region (2026-2032)
Figure 24. Global siRNA Drugs Revenue Market Share by Region in 2032
Figure 25. North America siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 26. Europe siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 27. Asia-Pacific siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 28. South America siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 29. Middle East & Africa siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 30. Global siRNA Drugs Market Share Forecast by Type (2026-2032)
Figure 31. Global siRNA Drugs Market Share Forecast by Application (2026-2032)
Figure 32. Methodology
Figure 33. Research Process and Data Source
Table 1. Global siRNA Drugs Revenue by Type, (USD Million) 2026 VS 2032
Table 2. Global siRNA Drugs Revenue by Application, (USD Million), 2026 VS 2032
Table 3. Alnylam Corporate Information, Head Office, and Major Competitors
Table 4. Alnylam Major Business
Table 5. Alnylam siRNA Drugs Product and Solutions
Table 6. Novartis Corporate Information, Head Office, and Major Competitors
Table 7. Novartis Major Business
Table 8. Novartis siRNA Drugs Product and Solutions
Table 9. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 10. Novo Nordisk Major Business
Table 11. Novo Nordisk siRNA Drugs Product and Solutions
Table 12. Genzyme Corporate Information, Head Office, and Major Competitors
Table 13. Genzyme Major Business
Table 14. Genzyme siRNA Drugs Product and Solutions
Table 15. Arrowhead Corporate Information, Head Office, and Major Competitors
Table 16. Arrowhead Major Business
Table 17. Arrowhead siRNA Drugs Product and Solutions
Table 18. Silence Corporate Information, Head Office, and Major Competitors
Table 19. Silence Major Business
Table 20. Silence siRNA Drugs Product and Solutions
Table 21. Sylentis Corporate Information, Head Office, and Major Competitors
Table 22. Sylentis Major Business
Table 23. Sylentis siRNA Drugs Product and Solutions
Table 24. Avidity Biosciences Corporate Information, Head Office, and Major Competitors
Table 25. Avidity Biosciences Major Business
Table 26. Avidity Biosciences siRNA Drugs Product and Solutions
Table 27. Sirnaomics Corporate Information, Head Office, and Major Competitors
Table 28. Sirnaomics Major Business
Table 29. Sirnaomics siRNA Drugs Product and Solutions
Table 30. Global siRNA Drugs Revenue (USD Million) by Players (2026 & 2032)
Table 31. Global siRNA Drugs Revenue Share by Players (2026 & 2032)
Table 32. siRNA Drugs Players Head Office, Products and Services Provided
Table 33. siRNA Drugs Mergers & Acquisitions in the Past Five Years
Table 34. siRNA Drugs New Entrants and Expansion Plans
Table 35. Global Market siRNA Drugs Revenue (USD Million) Comparison by Region (2026 VS 2032)
Table 36. Global siRNA Drugs Revenue Market Share by Region (2026-2032)
Table 37. Key Companies of siRNA Drugs in North America
Table 38. Current Situation and Forecast of siRNA Drugs in North America
Table 39. Key Companies of siRNA Drugs in Europe
Table 40. Current Situation and Forecast of siRNA Drugs in Europe
Table 41. Key Companies of siRNA Drugs in Asia-Pacific
Table 42. Current Situation and Forecast of siRNA Drugs in Asia-Pacific
Table 43. Key Companies of siRNA Drugs in China
Table 44. Key Companies of siRNA Drugs in Japan
Table 45. Key Companies of siRNA Drugs in South Korea
Table 46. Key Companies of siRNA Drugs in South America
Table 47. Current Situation and Forecast of siRNA Drugs in South America
Table 48. Key Companies of siRNA Drugs in Middle East & Africa
Table 49. Current Situation and Forecast of siRNA Drugs in Middle East & Africa
Table 50. Global siRNA Drugs Revenue Forecast by Type (2026-2032)
Table 51. Global siRNA Drugs Revenue Forecast by Application (2026-2032)
LIST OF FIGURES
Figure 1. siRNA Drugs Picture
Figure 2. Global siRNA Drugs Revenue Market Share by Type in 2032
Figure 3. Intravenous Injection
Figure 4. Subcutaneous Injection
Figure 5. siRNA Drugs Revenue Market Share by Application in 2032
Figure 6. Nervous System Therapy Picture
Figure 7. Endocrine and Metabolic Therapy Picture
Figure 8. Others Picture
Figure 9. Global siRNA Drugs Market Size, (USD Million): 2026 VS 2032
Figure 10. Global siRNA Drugs Revenue and Forecast (2026-2032) & (USD Million)
Figure 11. siRNA Drugs Market Drivers
Figure 12. siRNA Drugs Market Restraints
Figure 13. siRNA Drugs Market Trends
Figure 14. Alnylam Recent Developments and Future Plans
Figure 15. Novartis Recent Developments and Future Plans
Figure 16. Novo Nordisk Recent Developments and Future Plans
Figure 17. Genzyme Recent Developments and Future Plans
Figure 18. Arrowhead Recent Developments and Future Plans
Figure 19. Silence Recent Developments and Future Plans
Figure 20. Sylentis Recent Developments and Future Plans
Figure 21. Avidity Biosciences Recent Developments and Future Plans
Figure 22. Sirnaomics Recent Developments and Future Plans
Figure 23. Global siRNA Drugs Revenue Market Share by Region (2026-2032)
Figure 24. Global siRNA Drugs Revenue Market Share by Region in 2032
Figure 25. North America siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 26. Europe siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 27. Asia-Pacific siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 28. South America siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 29. Middle East & Africa siRNA Drugs Revenue (USD Million) and Growth Rate (2026-2032)
Figure 30. Global siRNA Drugs Market Share Forecast by Type (2026-2032)
Figure 31. Global siRNA Drugs Market Share Forecast by Application (2026-2032)
Figure 32. Methodology
Figure 33. Research Process and Data Source
